Purple Biotech Ltd. - American Depositary Shares (PPBT)
PPBT moved a median of 0.00% 30 minutes after news, and -1.48% by the close. How PPBT actually reacts to news — the realized, point-in-time move the market made, measured across 217 labeled events over the last three years with zero look-ahead.
PPBT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 32% | 188 |
| 30-min | 0.00% | 47% | 213 |
| 60-min | -0.39% | 41% | 215 |
| to close | -1.48% | 35% | 217 |
| Middle 50% of PPBT reactions | -2.33% to +2.19% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 217 |
Half of all Purple Biotech Ltd. - American Depositary Shares news events land between -2.33% and +2.19% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when PPBT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PPBT's baseline. Nothing else.
Recent PPBT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K PURPLE BIOTECH LTD. For: Oct 05 | SEC filing · Form 6-K | SEC EDGAR | — | -3.92% | |
| Form 6-K PURPLE BIOTECH LTD. For: Sep 09 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -5.95% | |
| Form 6-K PURPLE BIOTECH LTD. For: Sep 02 | SEC filing · Form 6-K | SEC EDGAR | -3.31% | -17.84% | |
| New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies | Press release | GlobeNewswire | -3.31% | -17.84% | |
| Form 6-K PURPLE BIOTECH LTD. For: Aug 07 | SEC filing · Form 6-K | SEC EDGAR | +3.16% | +5.93% | |
| Purple Biotech Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +3.16% | +5.93% | |
| Form 6-K PURPLE BIOTECH LTD. For: Jul 29 | SEC filing · Form 6-K | SEC EDGAR | — | -1.44% | |
| Form 6-K PURPLE BIOTECH LTD. For: Jun 23 | SEC filing · Form 6-K | SEC EDGAR | +2.98% | +5.36% | |
| Form 6-K PURPLE BIOTECH LTD. For: Jun 11 | SEC filing · Form 6-K | SEC EDGAR | -12.89% | -31.56% | |
| Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window | Press release | GlobeNewswire | -12.89% | -31.56% | |
| Form F-3 PURPLE BIOTECH LTD. | SEC filing · Form F-3 | SEC EDGAR | +3.26% | -2.17% | |
| Form 6-K PURPLE BIOTECH LTD. For: May 15 | SEC filing · Form 6-K | SEC EDGAR | — | -1.50% | |
| Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights | Press release | GlobeNewswire | — | -1.50% | |
| Form 6-K PURPLE BIOTECH LTD. For: Apr 27 | SEC filing · Form 6-K | SEC EDGAR | — | +2.00% | |
| Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240 | Press release | GlobeNewswire | — | +2.00% | |
| Form 6-K PURPLE BIOTECH LTD. For: Apr 23 | SEC filing · Form 6-K | SEC EDGAR | — | -9.54% | |
| Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform | Press release | GlobeNewswire | — | -9.54% | |
| Form 6-K PURPLE BIOTECH LTD. For: Mar 25 | SEC filing · Form 6-K | SEC EDGAR | +0.61% | +0.98% | |
| Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform | Press release | GlobeNewswire | +0.61% | +0.98% | |
| Form 20-F PURPLE BIOTECH LTD. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | — | -3.10% | |
| Form 6-K PURPLE BIOTECH LTD. For: Mar 18 | SEC filing · Form 6-K | SEC EDGAR | — | -3.10% | |
| Form 6-K PURPLE BIOTECH LTD. For: Mar 17 | SEC filing · Form 6-K | SEC EDGAR | -3.46% | -1.48% | |
| Purple Biotech Regains Compliance with Nasdaq | Press release | GlobeNewswire | -3.46% | -1.48% | |
| Form 6-K PURPLE BIOTECH LTD. For: Mar 13 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +7.05% | |
| Purple Biotech Announces CEO Transition | Press release | GlobeNewswire | +0.00% | +7.05% | |
| Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | +0.00% | +7.05% | |
| Form 6-K PURPLE BIOTECH LTD. For: Feb 25 | SEC filing · Form 6-K | SEC EDGAR | -0.14% | +1.43% | |
| Purple Biotech Announces Plan to Implement ADS Ratio Change | Press release | GlobeNewswire | -0.14% | +1.43% | |
| Form 6-K PURPLE BIOTECH LTD. For: Jan 12 | SEC filing · Form 6-K | SEC EDGAR | — | -1.77% | |
| Form 6-K PURPLE BIOTECH LTD. For: Jan 07 | SEC filing · Form 6-K | SEC EDGAR | +0.92% | +0.37% | |
| Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240 | Press release | GlobeNewswire | +0.92% | +0.37% | |
| Form 6-K PURPLE BIOTECH LTD. For: Dec 16 | SEC filing · Form 6-K | SEC EDGAR | +0.69% | +2.44% | |
| Form 6-K PURPLE BIOTECH LTD. For: Dec 11 | SEC filing · Form 6-K | SEC EDGAR | -2.85% | -3.29% | |
| Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025 | Press release | GlobeNewswire | -2.85% | -3.29% | |
| Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress | Press release | GlobeNewswire | -0.20% | +2.39% | |
| Form 6-K PURPLE BIOTECH LTD. For: Nov 19 | SEC filing · Form 6-K | SEC EDGAR | -4.88% | -4.75% | |
| Form 6-K PURPLE BIOTECH LTD. For: Nov 14 | SEC filing · Form 6-K | SEC EDGAR | -1.45% | -2.93% | |
| Form 6-K PURPLE BIOTECH LTD. For: Oct 29 | SEC filing · Form 6-K | SEC EDGAR | +0.47% | -0.94% | |
| Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform | Press release | GlobeNewswire | +0.47% | -0.94% | |
| Form 6-K PURPLE BIOTECH LTD. For: Oct 28 | SEC filing · Form 6-K | SEC EDGAR | +0.47% | -0.94% | |
| Form 6-K PURPLE BIOTECH LTD. For: Oct 20 | SEC filing · Form 6-K | SEC EDGAR | +3.49% | +0.96% | |
| Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification | Press release | GlobeNewswire | +3.49% | +0.96% | |
| Form 6-K PURPLE BIOTECH LTD. For: Sep 19 | SEC filing · Form 6-K | SEC EDGAR | -1.72% | -2.19% | |
| Form 6-K PURPLE BIOTECH LTD. For: Sep 15 | SEC filing · Form 6-K | SEC EDGAR | +0.20% | +4.82% | |
| Form 6-K PURPLE BIOTECH LTD. For: Sep 10 | SEC filing · Form 6-K | SEC EDGAR | -1.48% | -7.88% | |
| Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance | Press release | GlobeNewswire | -1.48% | -7.88% | |
| Form 6-K PURPLE BIOTECH LTD. For: Sep 05 | SEC filing · Form 6-K | SEC EDGAR | -2.90% | +4.08% | |
| Form EFFECT PURPLE BIOTECH LTD. | SEC filing · Form EFFECT | SEC EDGAR | -8.54% | -12.23% | |
| Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants | Press release | GlobeNewswire | +0.42% | -3.54% | |
| Form 6-K PURPLE BIOTECH LTD. For: Sep 04 | SEC filing · Form 6-K | SEC EDGAR | -13.59% | -13.33% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PPBT section they belong to.
Where else PPBT is measured.
PPBT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Purple Biotech Ltd. - American Depositary Shares's median reaction calculated?
Every labeled PPBT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 217 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of PPBT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PPBT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.